Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 108 clinical trials
Featured trial
AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD

AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD

  • 368 views
  • 08 Nov, 2020
  • 1 location
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Phase 2, single-arm, open, non-randomized, multicenter study of the SINE compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab. 100 mg selinexor

neutrophil count
proteasome inhibitor
monoclonal antibodies
colony stimulating factor
g-csf
  • 22 views
  • 05 Mar, 2022
  • 15 locations
Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR

and desensitization protocols, and mainly consisted of steroids, plasma exchange (PE), IVIG and RTX in various modalities. More recently, bortezomib was also proposed.To evaluate the role of a

  • 0 views
  • 24 Mar, 2022
  • 1 location
A Study of Evaluating the Safety and Efficacy of ATG-010 Bortezomib and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

This is a Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or

  • 0 views
  • 06 Oct, 2021
  • 28 locations
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease progression, discontinuation of study treatment due to unacceptable drug toxicity, or other reasons. Throughout the

  • 1 views
  • 16 Feb, 2022
  • 1 location
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

The purpose of this study is to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or

  • 0 views
  • 22 Mar, 2022
  • 1 location
Safety and Efficacy of Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment: A Prospective Phase II Trial (BID-PERAL)

This is an open-label, single-arm study to evaluate the safety and efficacy of bortezomib plus dexamethasone for acquired pure red cell aplasia failure or relapse after first-line treatment.

  • 0 views
  • 23 Sep, 2022
  • 1 location
BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)

To explore the effectiveness and safety of bortezomib, cyclophosphamide and dexamethasone (BCD regimen) in newly diagnosed idiopathic Multicentric Castleman's disease (iMCD) patients.

  • 1 views
  • 09 Feb, 2022
  • 1 location
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

patients with multiple myeloma who have achieved at least partial response (PR) or better after receiving a bortezomib- and lenalidomide-containing combination front-line therapy.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma

first-line treatment with high response rate. However, 65-84% SBP patients and 25-35% EMP patients progress at 10 years. We aimed to investigate whether adjuvant bortezomib based chemotherapy with

  • 0 views
  • 13 May, 2022
  • 1 location